Beta
Topotecan
medication Under reviewA chemotherapeutic agent and topoisomerase inhibitor used in the treatment of ovarian, cervical, and small cell lung cancers.
Research summary
The human clinical literature on topotecan is largely in patients with cancer rather than healthy volunteers. Phase I and phase II studies established that it has antitumor activity, but also that bone marrow suppression is a major toxicity, with leukopenia and thrombocytopenia being dose-limiting in early trials. Regulatory labeling and clinical trial data support its use as an oncology drug, not as a supplement. Because the requested focus is healthy human subjects, there are essentially no relevant healthy-subject studies for benefits, condition-specific effects, or supplement-style use. The available evidence instead documents adverse effects and drug-interaction concerns from therapeutic use in patients, so this entry is structured as a medication profile rather than a supplement profile.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Topotecan to your stack to report effects
Topotecan injection prescribing information
U.S. Food and Drug Administration
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Sandler et al.
No reports yet
Be the first to report this effect and help the community.
Add Topotecan to your stack to report effects
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Sandler et al.
Topotecan injection prescribing information
U.S. Food and Drug Administration
No reports yet
Be the first to report this effect and help the community.
Add Topotecan to your stack to report effects
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Sandler et al.
Topotecan injection prescribing information
U.S. Food and Drug Administration
No reports yet
Be the first to report this effect and help the community.
Add Topotecan to your stack to report effects
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Sandler et al.
Topotecan injection prescribing information
U.S. Food and Drug Administration
No reports yet
Be the first to report this effect and help the community.
Add Topotecan to your stack to report effects
Topotecan injection prescribing information
U.S. Food and Drug Administration
Research (2 studies)
Topotecan injection prescribing information
U.S. Food and Drug Administration
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Sandler et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!